Alrex Dosing
Alrex (loteprednol etabonate 0.2% ophthalmic suspension) is dosed as 1 drop into the affected eye(s) 4 times daily for the treatment of seasonal allergic conjunctivitis. 1
FDA-Approved Dosing Regimen
The standard dosing for Alrex is:
- Frequency: 1 drop 4 times per day
- Indication: Seasonal allergic conjunctivitis
- Duration: Clinical studies demonstrated efficacy over 6 weeks, with symptom reduction beginning approximately 2 hours after the first dose and continuing through 14 days of treatment 1
Important Monitoring Requirements
If Alrex is used for 10 days or longer, intraocular pressure (IOP) must be monitored 1. This is critical because:
- The initial prescription and any renewal beyond 14 days should only be made by a physician after examination with magnification (slit lamp biomicroscopy) 1
- If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated 1
Clinical Context from Guidelines
While the FDA label specifies dosing for allergic conjunctivitis, loteprednol formulations are referenced in clinical guidelines for other inflammatory conditions:
- For neuropathic corneal pain, loteprednol 0.5% (not the 0.2% Alrex formulation) is recommended 4 times daily for 2 weeks, then tapered to twice daily for 2 weeks, then once daily over 6-12 weeks 2
- Loteprednol is preferred over other corticosteroids due to lower rates of IOP elevation and cataract formation from decreased intraocular penetration 2
Safety Considerations
Key warnings:
- Do not use to treat contact lens-related irritation 1
- Patients should wait at least 10 minutes after instilling Alrex before inserting contact lenses 1
- The preservative benzalkonium chloride may be absorbed by soft contact lenses 1
- While generally safer than other steroids, rare cases of significant IOP elevation have been reported even with the 0.2% formulation 3
Long-Term Use Data
Research demonstrates that loteprednol etabonate 0.2% has been used safely for extended periods in allergic conjunctivitis, with no reported adverse effects in patients using it continuously for over 12 months 4. However, this extended use is off-label and requires appropriate monitoring.